ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)

Press/Media: Press / Media

PeriodApr 25 2015 → Apr 27 2015

Media coverage

16

Media coverage

  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletCNBC
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletBloomberg
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletReuters
    CountryUnited Kingdom
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletBusiness Wire
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletMorningstar.com
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletTMC Net
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletNasdaq
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletYahoo! UK and Ireland
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletEON: Enhanced Online News
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletWorld Energy Source
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletPharmacy Choice
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletI Stock Analyst
    CountryUnited States
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletBioPortfolio
    CountryUnited Kingdom
    Date4/27/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletPipelineReview
    CountrySpain
    Date4/25/15
    PersonsFred Poordad
  • TitleALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients with Cirrhosis (Child-Pugh Class A or B)
    Media name/outletBristol-Myers Squibb
    CountryUnited States
    Date4/25/15
    PersonsFred Poordad